News >

Expert Emphasizes Importance of Neoadjuvant Therapy in HER2+ Breast Cancer

Angelica Welch
Published: Tuesday, Nov 28, 2017

Dr. Patrick I. Borgen

Patrick I. Borgen, MD
Neoadjuvant strategies are underutilized in the treatment of HER2-positive breast cancer, says Patrick Borgen, MD.

, Borgen, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discussed the importance of neoadjuvant therapy in the treatment of patients with HER2-positive breast cancer.

OncLive: If a patient undergoes testing and it comes back that they have HER2 expression, what are some of the first things that you are thinking about?

Borgen: What has been amazing over the last 20 years of my career is how much the view of HER2-positive [disease] has changed. In the pre-HER2 blockade or pre-trastuzumab (Herceptin) era, HER2-postiivty was the worst possible thing that you could get on a biopsy result. One of the first papers that I ever added to my CV was about how bad it was to have HER2-positivity in the absence of treatment. Now…both single- and double-targeting of HER2 have really revolutionized the outcomes. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication